TouchPoint Solution, the creator of stress-relieving digital health wearable devices, showcased their patented BLAST technology and product lineup at the Consumer Electronics Show in Las Vegas, NV, from January 5th to January 8th. Presenting on Friday, January 6th at the Digital Health Stage, CEO Vicki Mayo focused on how digital health technology is capable of relieving stress and improving mental health.
TouchPoint Solution was founded in 2017 with the mission of bringing relief to millions of people who suffer from stress and anxiety. Developed over a decade by a team of neurologists, TouchPoints have been awarded nine patents and utilized more than 4 million times in 2021 alone.
Given the importance of mental health and the significant negative impact that stress creates, "we are excited to use BLAST® technology to provide real-time, noninvasive solutions to help both children and adults alike stress less and live more," Mayo said.
TouchPoints digital health wearables are proven through clinical trials to reduce stress by 70% in 30 seconds with its embedded patented Bi-Lateral Alternating Stimulus Tactile (BLAST) technology.
TouchPoints create calm and focus through a neuroscience-powered algorithm of gentle alternating micro-vibrations. This rhythm reduces the natural fight and flight response caused by stress and helps to return the body to a state of focus and control.
TouchPoints improve focus and help both children and adults alike by relieving symptoms of stress, anxiety, sleep issues, ADHD, autism, PTSD, epilepsy, Parkinson's disease, and more.
Team TouchPoint at #CES2023 in the Digital Health Lounge! Come experience BLAST (bi-lateral alternation stimulation tactile) with our stress relief wearables. pic.twitter.com/XGbJBY9z6l
— The TouchPoint Solution™ (@ilovetouchpoint) January 7, 2023
BioIntelliSense, a health monitoring, and clinical intelligence company was named a CES 2023 Innovation Awards Honoree for its BioButton medical-grade wearable and advanced data analytics that make vital sign monitoring simple and cost-effective from in-hospital to home.
BioIntelliSense medical-grade Data-as-a-Service (DaaS) platform captures vital signs, physiological biometrics, and symptomatic events through an effortless patient experience. The FDA-cleared BioButton wearable device makes remote monitoring and early detection simple. Through the platform’s advanced analytics, clinicians have access to high-resolution patient trending and reporting to enable medical-grade remote care from in-hospital to home.
“We’re proud to be honored once again with the prestigious CES Innovation Award,” said James Mault, MD, founder and CEO of BioIntelliSense. “Clinical intelligence is transforming tech-enabled healthcare and BioIntelliSense is committed to leading the way toward a future where data-driven, personalized, and proactive care is accessible and actionable anytime, anywhere. We’re thrilled to share our vision and technology at CES alongside fellow leaders delivering innovative solutions that are rapidly advancing the standard of care.”
An elite panel of industry expert judges, including members of the media, designers, engineers, and more, reviewed a record-high number of over 2,100 submissions based on innovation, engineering and functionality, aesthetics, and design.
The rechargeable BioButton is a patient-friendly wearable device that wirelessly transmits up to 1,440 sets of vital sign measurements per day. The device measures heart and respiratory rates at rest, and skin temperature trends, along with a broad range of physiological parameters, including sleep tracking, body position, activity levels, and gait analysis for a comprehensive, high-resolution view of a patient’s health status from in-hospital to at home.
>The BioButton® was recently been selected to monitor astronaut health during the upcoming Polaris Dawn space missions with SpaceX in partnership with the Translational Research Institute for Space Health.
The next #PolarisDawn space mission will include the #BioButton medical grade wearable for continuous physiologic monitoring to better understand human health during commercial space flight.
— BioIntelliSense, Inc. (@biointellisense) December 1, 2022
Details on our partnership w/@BCMSpaceHealth in @denbizjournal: https://t.co/MGf5npZOe5
